# Simulations Plus Craters on Lawsuits and Auditor Ouster; AI Pitch Fuels Tentative Rebound

> Simulations Plus sank after a revenue miss, auditor exit, and concerns over Pro-ficiency deal. Management touts AI updates, but investors want hard adoption and clean audits.

- Type: AI news
- Page: https://completeaitraining.com/news/simulations-plus-craters-on-lawsuits-and-auditor-ouster-ai/
- Published: 2025-10-27
- Updated: 2025-10-27
- Author: Jeroen Erne
- Jobs: Finance
- Reading time: 3 min

### Simulations Plus: Steep Selloff, Legal Overhang, and an AI Pitch Investors Are Testing

Simulations Plus (NASDAQ: SLP) is in the penalty box. A revenue miss, auditor dismissal, and integration problems have turned sentiment fast, even as management leans into an AI product push to steady growth.

#### What happened

Q3 2025 revenue came in at $20.4 million, up 10% year over year but below the $20.9 million consensus. Prior guidance in June telegraphed softness at $19-20 million versus $22.78 million expected, so the miss wasn't a complete surprise. Shares still fell 25.75% on July 15, 2025, as confidence cracked around execution and disclosure.

Post-earnings, two law firms launched securities class action investigations tied to alleged misstatements, including representations about the 2024 Pro-ficiency acquisition. The deal was pitched as doubling the addressable market; integration has since drawn scrutiny.

#### Legal and accounting overhang

In June 2025, the company dismissed auditor Grant Thornton after disputes over segment reporting and internal controls. Management also recorded a $77.2 million impairment related to prior acquisitions. Together, these items amplified the risk narrative around reporting reliability and M&A discipline.

Investigations by the Rosen Law Firm and Bleichmar Fonti & Auld LLP are ongoing and focus on alleged inaccuracies tied to financial condition and Pro-ficiency integration. Allegations are not findings; outcomes remain uncertain.

#### Strategy: AI-forward product updates

CEO Shawn O'Connor reiterated revised 2025 targets and highlighted an AI-driven roadmap across cloud and simulation tools. The pitch: faster workflows, better predictability in R&D modeling, and broader adoption across biopharma workflows.

The key question for investors is conversion, not concepts. Watch for proof points in attach rates, net retention, pricing, and time-to-value within key modules.

#### Street view and ownership shifts

Coverage is split. Cowen initiated with a hold in September 2025. William Blair remains at outperform. KeyCorp moved to sector weight in July amid higher uncertainty. On the buy side, Stephens Investment Management Group disclosed a new $4.69 million position.

#### Operational friction points

Pro-ficiency integration challenges and control deficiencies have been cited as drags on execution. External headwinds-drug pricing pressure and tariff exposure-add noise to forecasting and deal timing.

#### Numbers to model

- Q3 2025 revenue: $20.4 million (10% y/y), below $20.9 million consensus
- Impairment charges: $77.2 million linked to acquisitions
- FY2026 revenue guide: $79-$82 million, implying 0-4% growth
- Key date: Full-year 2025 results on December 1, 2025

#### Key risks

- Audit and control issues: lingering investor trust gap until resolved and communicated clearly
- Integration execution: Pro-ficiency synergy capture vs. churn and distraction risk
- Regulatory and pricing pressure: budget cycles at pharma clients can slip
- Litigation: potential costs and management bandwidth drain

#### Catalysts to watch

- Clean audit updates and control remediation milestones
- Retention and cross-sell data that prove AI features are sticky and monetizable
- Deal velocity in core modeling suites and Pro-ficiency modules
- Any change to FY2026 outlook as visibility improves

#### Practical checklist for finance teams

- Validate disclosure quality: review filings and auditor notes for control remediation updates. Consider monitoring [SEC EDGAR](https://www.sec.gov/edgar/browse/?CIK=0001023459&ref=completeaitraining.com) for fresh 8-Ks and 10-Q/10-K details.
- Separate signal from impairment noise: focus on cash metrics, deferred revenue trends, and ARR growth to gauge core health.
- Interrogate the AI story: ask for module-level adoption, win rates against peers, pricing uplift, and customer time-to-value.
- Scenario test FY2026: bracket outcomes for flat vs. modest growth, factoring legal costs and integration spend.
- Watch the tape: liquidity dislocations post-legal headlines can be temporary, but they often repeat if control fixes lag.

#### Bottom line

The bear case hinges on control issues, litigation risk, and an integration that still needs proof. The bull case needs hard adoption data from AI-driven products and a clean compliance narrative-fast.

Until those show up in filings and in the numbers, expect a valuation that trades on trust as much as revenue growth.

**Resources**

- Company quote and trading data: [NASDAQ: SLP](https://www.nasdaq.com/market-activity/stocks/slp?ref=completeaitraining.com)
- For teams evaluating AI tooling in finance workflows: [AI tools for finance](https://completeaitraining.com/ai-tools/10b-ai-tools-for-finance/)

**Disclaimer:** This content is for informational purposes only and is not investment advice or a recommendation to buy or sell any security.

---

This is the Markdown form of https://completeaitraining.com/news/simulations-plus-craters-on-lawsuits-and-auditor-ouster-ai/. The whole site is mapped at https://completeaitraining.com/llms.txt.
